RxDoctor Payments Data

Kimberly Macdonald

Family · Williamsville, NYNPI 1598722365

Payments from drug & device makers

$6,000in general payments, 2019–2025

Across 349 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$922
  • Lilly USA, LLC$714
  • AbbVie$503
  • Exact Sciences$478
  • GSK$367
  • Boehringer Ingelheim$312
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,000100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,000 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$15,659
Medicare patients
86
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$39,843
EliquisApixaban29$27,636
JardianceEmpagliflozin12$11,057
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,548
Breo ElliptaFluticasone/Vilanterol11$5,921
Levothyroxine Sodium198$4,111
Atorvastatin Calcium213$3,178
Rosuvastatin Calcium104$1,871
Irbesartan33$1,627
Fluticasone Propionate90$1,486
Albuterol Sulfate HfaAlbuterol Sulfate37$1,447
Lisinopril139$1,432
SynthroidLevothyroxine Sodium18$1,341
Omeprazole95$1,303
Bupropion XlBupropion Hcl36$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$922$39,84335 claims
PfizerEliquis$169$27,63629 claims
Boehringer IngelheimJardiance$312$11,05712 claims
GSKBreo Ellipta$367$5,92111 claims
AbbVieSynthroid$503$1,34118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →